The GLCCI1 rs37973 variant and the efficacy of inhaled corticosteroids in the treatment of asthma: A meta‐analysis
The Clinical Respiratory Journal · 2023
DOI: 10.1111/crj.13627 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Clinical Respiratory Journal, 2023. Verfasst von Wen-Ling Feng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research on Precision Medicine at the State Key Laboratory of Pathogenesis, Prevention and Treatment of Central Asian High Incidence Diseases Fund.
Abstract (Originalsprache)
Objective
This study investigated the relationship between the glucocorticoid‐induced transcript 1 ( GLCCI1 ) gene variant and the degree of improvement in lung function with inhaled corticosteroids (ICS).
Methods
We searched the PubMed, Embase, Cochrane Library, CBM, CNKI and Wanfang databases to obtain studies on the GLCCI1 rs37973 variant and the efficacy of ICS in asthma.
Results
The overall meta‐analysis showed that patients with the GG phenotype (mutant homozygotes) exhibited significantly smaller forced expiratory volume in 1 sec (FEV1) change than patients with the AG phenotype (mutant heterozygous) (MD = −0.08, 95% CI [−0.12, −0.03], P = 0.001). Compared with the AA phenotype (wild homozygotes), the GG phenotype (MD = −4.23, 95% CI [−6.09, −2.38], P < 0.00001) and AG phenotype (MD = −1.92, 95% CI [−2.35, −1.49], P < 0.00001) had significantly smaller FEV1%pred changes. The FEV1 change subgroup analysis showed that the GG phenotype group was smaller than the AA phenotype group at 8 (MD = −0.53, 95% CI [−0.91, −0.14], P = 0.007), 12 (MD = −0.16, 95% CI [−0.30, −0.02], P = 0.02) and 24 (MD = −0.09, 95% CI [−0.17, −0.01], P = 0.02) weeks of treatment; the GG phenotype group was smaller than the AG phenotype group at 12 weeks (MD = −0.08, 95% CI [−0.15, −0.01], P = 0.02).
Conclusion
This meta‐analysis suggests that the GLCCI1 rs37973 variant affects the efficacy of ICS and that the presence of the G allele attenuates the improvement in lung function with ICS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
- College of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang, China.
- State Key Laboratory of Pathogenesis, Prevention, and Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjia…
ORCID-Profile: Jun Zhao
Förderung
- Research on Precision Medicine at the State Key Laboratory of Pathogenesis, Prevention and Treatment of Central Asian High Incidence Diseases Fund
Zitieren
APA
Feng, W. L., Pu, W., Li, J., Yuan, Y., Yan, M. Z., Yuan, S. L., Li, Y. K., Wu, J. R., Xu, S. Q., & Zhao, J. (2023). The GLCCI1 rs37973 variant and the efficacy of inhaled corticosteroids in the treatment of asthma: A meta‐analysis. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.13627
Vancouver
Feng WL, Pu W, Li J, Yuan Y, Yan MZ, Yuan SL, et al. The GLCCI1 rs37973 variant and the efficacy of inhaled corticosteroids in the treatment of asthma: A meta‐analysis. The Clinical Respiratory Journal. 2023. doi:10.1111/crj.13627
BibTeX
@article{Feng2023,
author = {Feng, Wen-Ling and Pu, Wen and Li, Jing and Yuan, Yuan and Yan, Ming-Zhi and Yuan, Shuang-Li and Li, Yu-Kun and Wu, Jie-Ru and Xu, Shao-Quan and Zhao, Jun},
title = {The GLCCI1 rs37973 variant and the efficacy of inhaled corticosteroids in the treatment of asthma: A meta‐analysis},
journal = {The Clinical Respiratory Journal},
year = {2023},
doi = {10.1111/crj.13627}
}
EUVIMED